경장 영양제(Enteral Feeding Formulas) 시장 : 2027 년까지 세계 예측

출판 : MarketsandMarkets(마켓츠앤마켓츠)출판년월 : 2022년08월

경장 영양제(Enteral Feeding Formulas) 시장 : 제품 (중합체, 원소, 질병별), 단계 (성인, 소아과), 용도 (종양학, 소화기 병학, 신경학, 대사 항진), 최종 사용자 (병원, LTCF, 가정 의료) – 2027 년까지 세계 예측
Enteral Feeding Formulas Market by Product (Polymeric, Elemental, Disease-specific), Stage (Adults, Pediatrics), Application (Oncology, Gastroenterology, Neurology, Hypermetabolism), End User (Hospitals, LTCF, Home care) – Global Forecast to 2027

페이지수 224
도표수 279
구성 영문조사보고서
가격 이곳을 눌러주세요

리포트목차    주문/문의    납기/라이센스안내

Sample Request

The global enteral feeding formula market is projected to reach USD 8.2 billion by 2027 from USD 5.2 billion in 2022, growing at a CAGR of 9.5% during the forecast period. Over the years, enteral feeding formula have received importance in the healthcare industry, due to their various advantages over the traditional methods of nutrition administration, such as parenteral nutrition. Apart from being cost-intensive, parenteral nutrition is also associated with complications such as infections. Thus, the demand for enteral feeding formula is growing globally.
전 세계 경장 영양제 시장은 예측 기간 동안 9.5%의 CAGR로 2022년 52억 달러에서 2027년 82억 달러에 이를 것으로 예상됩니다. 수년에 걸쳐, 경장 영양제은 비경구 영양과 같은 전통적인 영양 투여 방법에 비해 다양한 이점으로 인해 의료 산업에서 중요성을 받아왔습니다. 비용 집약적인 것 외에도 비경구 영양은 감염과 같은 합병증과도 관련이 있습니다. 따라서, 경장 영양제에 대한 수요는 전 세계적으로 증가하고 있습니다.

경장 영양제(Enteral Feeding Formulas) 시장 : 제품 (중합체, 원소, 질병별), 단계 (성인, 소아과), 용도 (종양학, 소화기 병학, 신경학, 대사 항진), 최종 사용자 (병원, LTCF, 가정 의료) - 2027 년까지 세계 예측

Factors such as rising healthcare costs; a surge in the number of preterm births; growth in the aging population; rising prevalence of chronic diseases such as diabetes, cancer, gastrointestinal diseases, and neurological disorders; growing awareness of enteral nutrition; and rapid improvements in healthcare facilities in emerging countries are expected to further drive the market during the forecast period. Moreover, the shift from parenteral nutrition to enteral nutrition and growing adoption of and demand for enteral feeding formula in long term care facilities are also expected to drive the market in the coming years. In addition, insufficient or lack of reimbursements in some developing and underdeveloped countries and a dearth of trained physicians across the globe pose significant challenges for the growth of this market.

Based on product, the standard formula segment holds the largest share during the forecast period.

Based on product, the enteral feeding formulas market is segmented into standard (polymeric), peptide-based (elemental/semi-elemental), disease-specific, and other formulas. In 2021 standard formulas held the largest share, followed by disease-specific formulas. Standard formulas are easily available and widely used to fulfill daily requirements. The rising prevalence of target ailments thus plays a greater role in driving demand for standard formulas.

Based on application, the oncology segment holds the highest growth during the forecast period.

In 2021, the oncology segment accounted for the largest share of the enteral feeding formula market, followed by gastrointestinal diseases, neurological disorders, diabetes, and other applications. Increasing burden of cancer, the shift from hospitals to ambulatory care settings and the rising adoption of enteral feeding as an efficient alternative to parenteral nutrition among cancer patients are likely to fuel the demand for enteral feeding formulas in oncological applications.

Based on age group, the adult segment holds the largest share during the forecast period
Based on age group, the enteral feeding formula market is segmented into adult patients (18 years and over) and pediatric patients (neonates under 1 month, infants between 1 month and 2 years of age, children between 2 and 12 years, and adolescents between 12 and 16 years). In 2021, there has been a increase in adult patients accounted for a larger market share. This can be attributed to the growing incidence of cancer in adult patients, As most cancer patients suffer from malnutrition, an increase in cancer cases is expected to increase the demand for effective enteral nutrition. Also increase in chronic diseases are resulting in malnutrition and the rapid increase in the geriatric population are positively impacting market.

Based on end user, the long term care facilities holds the higher market share during the forecast period.

In 2021, Long term care facilities have a higher CAGR. Patients suffering from chronic diseases and disorders are advised long-term care or home care, depending upon the severity of the disease/disorder. Due to the increasing pressure on hospitals to curtail the soaring healthcare costs and the COVID-19 outbreak, there has been a shift from extended hospital treatment toward treatment at home. Studies reveal that home enteral nutrition (HEN) is significantly cheaper than home parenteral nutrition in the US. Growing awareness of therapeutic nutrition has contributed to the use of enteral nutrition products by patients at home.Thus end user segment registered higher market share.

APAC is expected to grow at the highest growth rate in 2021
During the forecast period, the Asia Pacific is estimated to be the fastest-growing regional market for enteral feeding formula. Several factors, such as the rising geriatric population, increased awareness of and accessibility to advanced healthcare facilities, rising healthcare spending, the growing focus of key market players on emerging APAC countries, and rapid improvements in the health insurance sector are driving the market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Company: Tier 1- 60%, Tier 2 – 30%, and Tier 3- 10%
• By Designation: C-Level- 30%%, Director level – 50%, and Others – 20%
• By Region: North America -45%, Europe -15%, Asia-Pacific -25%, Latin America – 10%, and Middle East and Africa – 5%

Key players in the enteral feeding formula market
Prominent players in this market include Abbott (US), Nestlé S.A. (Switzerland), Danone S.A. (France), Fresenius Kabi (Germany), B. Braun Melsungen AG (Germany), Otsuka Holding Co. Ltd. (Japan), Nutritional Medicinals, LLC (US), Kate Farms (US), Medtrition Inc. (US), Victus, Inc. (US), Global Health Products, Inc. (US), Meiji Holdings Co., Ltd. (Japan), Reckitt Benckiser Group PLC. (UK), Hormel Foods Corporation (US), DermaRite Industries, LLC. (US), Medline Industries, LP. (US), Real Food Blends (US), and Ajinomoto Cambrooke, Inc. (US).

경장 영양제(Enteral Feeding Formulas) 시장 : 제품 (중합체, 원소, 질병별), 단계 (성인, 소아과), 용도 (종양학, 소화기 병학, 신경학, 대사 항진), 최종 사용자 (병원, LTCF, 가정 의료) - 2027 년까지 세계 예측
Research Coverage:
The report analyzes the enteral feeding formula market and aims at estimating the market size and future growth potential of this market based on various segments such as product, stage, application, end user and region. The report also includes a product portfolio matrix of various enteral feeding products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.
This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global enteral feeding formula market. The report analyzes this market by product, stage, application, end user, and region
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global enteral feeding formula market
• Market Development: Comprehensive information on the lucrative emerging markets by product type, age group, application, end user, and region
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global enteral feeding formula market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global enteral feeding formula market.


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 33)
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 STUDY SCOPE
FIGURE 1 ENTERAL FEEDING FORMULAS MARKET
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 37)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 ENTERAL FEEDING FORMULAS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ENTERAL FEEDING FORMULAS
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 ENTERAL FEEDING FORMULAS MARKET: CAGR PROJECTIONS, 2022–2027
FIGURE 8 ENTERAL FEEDING FORMULAS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. – 49)
FIGURE 12 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 13 ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2022 VS. 2027 (USD MILLION)
FIGURE 14 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 15 ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 16 GEOGRAPHIC ANALYSIS: ENTERAL FEEDING FORMULAS MARKET

4 PREMIUM INSIGHTS (Page No. – 53)
4.1 ENTERAL FEEDING FORMULAS MARKET OVERVIEW
FIGURE 17 INCREASING PREVALENCE OF CHRONIC DISEASES AND SHIFT FROM PARENTERAL NUTRITION TO ENTERAL NUTRITION TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY TYPE (2022)
FIGURE 18 STANDARD FORMULAS TO DOMINATE APAC ENTERAL FEEDING FORMULAS MARKET IN 2022
4.3 ENTERAL FEEDING FORMULAS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 MARKET IN CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.4 ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027
FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE ENTERAL FEEDING FORMULAS MARKET TILL 2027

5 MARKET OVERVIEW (Page No. – 57)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 ENTERAL FEEDING FORMULAS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Benefits and cost-effectiveness of enteral over parenteral nutrition
5.2.1.2 Rising preterm births fueling demand for enteral feeding formulas
FIGURE 22 US: TOTAL NUMBER OF PRETERM BIRTHS, 2010–2020
5.2.1.3 Growing demand for enteral feeding in home care
5.2.1.4 Rapid growth in geriatric population and disease prevalence
FIGURE 23 ESTIMATED DIABETIC POPULATION, BY REGION, 2019 VS. 2030 VS. 2040
FIGURE 24 GLOBAL CANCER INCIDENCE, 2015–2040
FIGURE 25 US: NUMBER OF PEOPLE WITH CHRONIC CONDITIONS, 1995–2030 (MILLION INDIVIDUALS)
TABLE 1 DRIVERS: IMPACT ANALYSIS
5.2.2 RESTRAINTS
5.2.2.1 Complications associated with enteral feeding
TABLE 2 COMPLICATIONS ASSOCIATED WITH ENTERAL FEEDING
5.2.2.2 Lack of patient awareness
TABLE 3 RESTRAINTS: IMPACT ANALYSIS
5.2.3 OPPORTUNITIES
5.2.3.1 Emergence of new products and innovation
5.2.3.2 High growth opportunities in emerging countries
TABLE 4 OPPORTUNITIES: IMPACT ANALYSIS
5.2.4 CHALLENGES
5.2.4.1 Insufficient reimbursements for enteral nutrition
5.2.4.2 Dearth of skilled professionals
TABLE 5 CHALLENGES: IMPACT ANALYSIS
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT FROM NEW ENTRANTS
5.3.2 THREAT FROM SUBSTITUTES
5.3.3 BARGAINING POWER OF SUPPLIERS
5.3.4 BARGAINING POWER OF BUYERS
5.3.5 COMPETITIVE RIVALRY
5.4 REGULATORY SCENARIO
5.4.1 REGULATORY ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 26 ENTERAL FEEDING FORMULAS MARKET: VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 27 ENTERAL FEEDING FORMULAS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM MARKET MAP
FIGURE 28 ENTERAL FEEDING FORMULAS MARKET: ECOSYSTEM MARKET MAP
5.8 PRICING ANALYSIS
TABLE 7 AVERAGE PRICE OF ENTERAL FEEDING FORMULAS, IN USD (2021)
TABLE 8 AVERAGE SELLING PRICES OF ENTERAL FEEDING FORMULAS, 2017–2021 (USD)
5.9 PATENT ANALYSIS
FIGURE 29 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR ENTERAL FEEDING FORMULA PATENTS (JANUARY 2011–OCTOBER 2021)
TABLE 9 INDICATIVE LIST OF PATENTS IN ENTERAL FEEDING FORMULAS MARKET
5.10 KEY CONFERENCES AND EVENTS IN 2022–2023
TABLE 10 ENTERAL FEEDING FORMULAS MARKET: LIST OF CONFERENCES AND EVENTS
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 30 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR ENTERAL FEEDING PRODUCTS
5.12 KEY BUYING CRITERIA FOR END USERS
FIGURE 31 ENTERAL FEEDING FORMULAS MARKET: BUYING CRITERIA OF END USERS

6 ENTERAL FEEDING FORMULAS MARKET, BY STAGE (Page No. – 78)
6.1 INTRODUCTION
TABLE 11 ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
6.2 ADULTS
6.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND NEUROLOGICAL DISORDERS IN ADULT PATIENTS TO INCREASE MARKET SHARE
TABLE 12 ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 14 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ADULTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 PEDIATRICS
6.3.1 GROWING DISEASE PREVALENCE IN PEDIATRIC PATIENTS DRIVING MARKET GROWTH
TABLE 16 ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR PEDIATRICS, BY COUNTRY, 2020–2027 (USD MILLION)

7 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT (Page No. – 85)
7.1 INTRODUCTION
TABLE 20 ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
7.2 STANDARD FORMULAS
7.2.1 EASE OF ACCESSIBILITY AND COST-EFFECTIVENESS WILL INCREASE MARKET GROWTH
TABLE 21 STANDARD ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 22 NORTH AMERICA: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 EUROPE: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 ASIA PACIFIC: STANDARD ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 DISEASE-SPECIFIC FORMULAS
TABLE 25 DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 26 DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NORTH AMERICA: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 EUROPE: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 ASIA PACIFIC: DISEASE-SPECIFIC ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.1 DIABETIC FORMULAS
7.3.1.1 Increased incidence of diabetes patients driving market growth
TABLE 30 DIABETIC FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 EUROPE: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 ASIA PACIFIC: DIABETIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.2 RENAL FORMULAS
7.3.2.1 Rise in patient population for chronic kidney disease to contribute to market growth
TABLE 34 RENAL FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: RENAL FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 EUROPE: RENAL FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 ASIA PACIFIC: RENAL FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.3 HEPATIC FORMULAS
7.3.3.1 Rise in obesity and alcohol consumption drive demand for hepatic formulas
TABLE 38 HEPATIC FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 ASIA PACIFIC: HEPATIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.4 PULMONARY FORMULAS
7.3.4.1 Rising disease prevalence to drive demand growth
TABLE 42 PULMONARY FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 EUROPE: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 ASIA PACIFIC: PULMONARY FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3.5 OTHER DISEASE-SPECIFIC FORMULAS
TABLE 46 OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 ASIA PACIFIC: OTHER DISEASE-SPECIFIC FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 PEPTIDE-BASED FORMULAS
7.4.1 BENEFITS OF PEPTIDE-BASED FORMULAS OVER OTHER SEGMENTS POSITIVELY IMPACTING MARKET GROWTH
TABLE 50 PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 EUROPE: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: PEPTIDE-BASED ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 OTHER FORMULAS
TABLE 54 OTHER ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: OTHER ENTERAL FEEDING FORMULAS MARKET, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: OTHER ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: OTHER ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

8 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION (Page No. – 104)
8.1 INTRODUCTION
TABLE 58 ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 ONCOLOGY
8.2.1 GROWING INCIDENCE OF CANCER TO INCREASE MARKET SHARE
TABLE 59 NUMBER OF NEW CANCER PATIENTS IN AMERICA
TABLE 60 ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 61 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 GASTROENTEROLOGY
8.3.1 INCREASING INCIDENCE OF GASTROINTESTINAL DISEASES TO DRIVE ADOPTION OF ENTERAL FEEDING FORMULAS
TABLE 64 INDICATIVE LIST OF DIGESTIVE DISEASES & DISORDERS REQUIRING ENTERAL FEEDING
TABLE 65 ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR GASTROENTEROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 NEUROLOGY
8.4.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO FUEL DEMAND FOR CLINICAL NUTRITION THERAPIES
TABLE 69 ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 71 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 72 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR NEUROLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 DIABETES
8.5.1 USE OF ENTERAL FEEDING SYSTEMS IN DIABETICS HELPS PREVENT HYPERGLYCEMIA AND ASSOCIATED COMPLICATIONS
TABLE 73 ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY REGION, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 75 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR DIABETES, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 77 ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 80 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 ENTERAL FEEDING FORMULAS MARKET, BY END USER (Page No. – 117)
9.1 INTRODUCTION
TABLE 81 ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITALS
9.2.1 GROWING CHRONIC AND INFECTIOUS DISEASE PREVALENCE DRIVES MARKET GROWTH
TABLE 82 ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION)
TABLE 83 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 85 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 LONG-TERM CARE FACILITIES
TABLE 86 ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 88 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 89 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.1 NURSING HOMES
9.3.1.1 Need for nursing care in above-65 age group to drive market growth
TABLE 91 ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY REGION, 2020–2027 (USD MILLION)
TABLE 92 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 93 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR NURSING HOMES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.2 ASSISTED LIVING FACILITIES
9.3.2.1 Growth in chronic disease prevalence to support market growth
TABLE 95 ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 96 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 97 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR ASSISTED LIVING FACILITIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3.3 HOME CARE AGENCIES & HOSPICES
9.3.3.1 Limitations associated with home care to hamper market growth
TABLE 99 ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 101 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 102 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR HOME CARE AGENCIES & HOSPICES, BY COUNTRY, 2020–2027 (USD MILLION)

10 ENTERAL FEEDING FORMULAS MARKET, BY REGION (Page No. – 128)
10.1 INTRODUCTION
TABLE 103 ENTERAL FEEDING FORMULAS MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 32 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET SNAPSHOT, 2021
TABLE 104 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 105 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 106 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 107 NORTH AMERICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 109 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 110 NORTH AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Advanced healthcare system and availability of reimbursement for enteral nutrition to increase market growth
TABLE 111 US: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 112 US: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 113 US: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 114 US: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 115 US: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 116 US: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing incidence of chronic diseases such as diabetes and cancer supports market growth
TABLE 117 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 118 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 119 CANADA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 120 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 121 CANADA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 122 CANADA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 123 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 124 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 125 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 126 EUROPE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 128 EUROPE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 129 EUROPE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.3.1 UK
10.3.1.1 High incidence of target diseases to drive UK enteral feeding formulas market
TABLE 130 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN UK
TABLE 131 UK: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 132 UK: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 133 UK: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 UK: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 135 UK: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 136 UK: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Germany to overtake UK and dominate European market by 2027
TABLE 137 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN GERMANY
TABLE 138 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 139 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 140 GERMANY: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 141 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 142 GERMANY: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 143 GERMANY: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Well-established healthcare system and strong government support contribute to market growth
TABLE 144 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN FRANCE
TABLE 145 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 146 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 147 FRANCE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 149 FRANCE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 150 FRANCE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Market growth attributed to growing geriatric population and need for nursing homes in Italy
TABLE 151 MACROINDICATORS FOR ENTERAL FEEDING FORMULAS MARKET IN ITALY
TABLE 152 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 153 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 154 ITALY: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 155 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 156 ITALY: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 157 ITALY: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Significant increase in patients opting for enteral nutrition to support market growth
TABLE 158 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 159 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 160 SPAIN: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 161 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 162 SPAIN: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 163 SPAIN: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 164 ROE: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 165 ROE: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 166 ROE: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 ROE: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 168 ROE: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 169 ROE: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 33 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET SNAPSHOT
TABLE 170 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 171 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 172 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 173 ASIA PACIFIC: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 175 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 176 ASIA PACIFIC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Rising geriatric population to drive market growth in Japan
TABLE 177 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 178 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 179 JAPAN: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 180 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 181 JAPAN: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 182 JAPAN: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Growing investment in healthcare infrastructure development to drive adoption of enteral feeding formulas
TABLE 183 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 184 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 185 CHINA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 186 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 187 CHINA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 188 CHINA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Increasing incidence of preterm births and cancer cases to drive market growth in India
TABLE 189 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 190 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 191 INDIA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 192 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 193 INDIA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 194 INDIA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 195 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 196 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 197 ROAPAC: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 199 ROAPAC: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 200 ROAPAC: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 ECONOMIC DEVELOPMENT, INCREASING HEALTHCARE ACCESS, AND GROWING DISEASE PREVALENCE TO DRIVE MARKET GROWTH
TABLE 201 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 202 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 203 LATIN AMERICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 204 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 205 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 206 LATIN AMERICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND HEALTH INSURANCE PENETRATION TO SUPPORT MARKET GROWTH
TABLE 207 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY STAGE, 2020–2027 (USD MILLION)
TABLE 208 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 209 MIDDLE EAST AND AFRICA: DISEASE-SPECIFIC FORMULAS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 210 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 211 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET, BY END USER, 2020–2027 USD MILLION)
TABLE 212 MIDDLE EAST AND AFRICA: ENTERAL FEEDING FORMULAS MARKET FOR LONG-TERM CARE FACILITIES, BY TYPE, 2020–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. – 181)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 34 KEY PLAYER STRATEGIES IN ENTERAL FEEDING FORMULAS MARKET, 2019–2022
11.3 MARKET SHARE ANALYSIS
FIGURE 35 ENTERAL FEEDING FORMULAS MARKET: MARKET SHARE ANALYSIS, 2021 (TOP FIVE PLAYERS)
TABLE 213 ENTERAL FEEDING FORMULAS MARKET: DEGREE OF COMPETITION
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 36 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ENTERAL FEEDING FORMULAS MARKET
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 37 ENTERAL FEEDING FORMULAS MARKET: COMPANY EVALUATION QUADRANT, 2021
11.6 COMPETITIVE BENCHMARKING
11.6.1 COMPANY FOOTPRINT ANALYSIS
FIGURE 38 COMPANY FOOTPRINT ANALYSIS
11.6.2 COMPANY PRODUCT FOOTPRINT
TABLE 214 PRODUCT PORTFOLIO ANALYSIS
11.6.3 COMPANY REGIONAL FOOTPRINT
TABLE 215 REGIONAL REVENUE MIX
11.6.3.1 COMPETITIVE BENCHMARKING
TABLE 216 ENTERAL FEEDING FORMULAS MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 217 ENTERAL FEEDING FORMULAS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES)
11.7 COMPETITIVE SCENARIO AND TRENDS
TABLE 218 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–JULY 2022
TABLE 219 DEALS, JANUARY 2019–JULY 2022
TABLE 220 OTHER DEVELOPMENTS, JANUARY 2019–JULY 2022

12 COMPANY PROFILES (Page No. – 193)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT
TABLE 221 ABBOTT: BUSINESS OVERVIEW
FIGURE 39 ABBOTT: COMPANY SNAPSHOT (2021)
12.1.2 NESTLÉ
TABLE 222 NESTLÉ: BUSINESS OVERVIEW
FIGURE 40 NESTLÉ: COMPANY SNAPSHOT (2021)
12.1.3 DANONE S.A.
TABLE 223 DANONE: BUSINESS OVERVIEW
FIGURE 41 DANONE: COMPANY SNAPSHOT (2021)
12.1.4 FRESENIUS KABI
TABLE 224 FRESENIUS KABI: BUSINESS OVERVIEW
FIGURE 42 FRESENIUS KABI: COMPANY SNAPSHOT (2021)
12.1.5 B. BRAUN MELSUNGEN AG
TABLE 225 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
FIGURE 43 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2021)
12.1.6 OTSUKA HOLDINGS CO., LTD.
TABLE 226 OTSUKA HOLDINGS CO., LTD.: BUSINESS OVERVIEW
FIGURE 44 OTSUKA HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2021)
12.1.7 NUTRITIONAL MEDICINALS, LLC
TABLE 227 NUTRITIONAL MEDICINALS, LLC: BUSINESS OVERVIEW
12.1.8 KATE FARMS
TABLE 228 KATE FARMS: BUSINESS OVERVIEW
12.1.9 MEDTRITION INC.
TABLE 229 MEDTRITION INC.: BUSINESS OVERVIEW
12.1.10 VICTUS, INC.
TABLE 230 VICTUS, INC.: BUSINESS OVERVIEW
12.1.11 GLOBAL HEALTH PRODUCTS, INC.
TABLE 231 GLOBAL HEALTH PRODUCTS, INC.: BUSINESS OVERVIEW
12.1.12 MEIJI HOLDINGS
TABLE 232 MEIJI HOLDINGS CO., LTD.: BUSINESS OVERVIEW
FIGURE 45 MEIJI HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2021)
12.1.13 RECKITT BENCKISER GROUP
TABLE 233 RECKITT BENCKISER GROUP: BUSINESS OVERVIEW
FIGURE 46 RECKITT BENCKISER GROUP: COMPANY SNAPSHOT (2021)
12.2 OTHER COMPANIES
12.2.1 HORMEL FOODS CORPORATION
12.2.2 DERMARITE INDUSTRIES
12.2.3 MEDLINE INDUSTRIES, LP
12.2.4 REAL FOOD BLENDS
12.2.5 AJINOMOTO CAMBROOKE, INC.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. – 226)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com